March 2023

Case report: Youngest patient ever treated with denovoSkin – a neonatal case

The paper published in Burns Open has presented the case of a four day-old neonate suffering from life threatening burns, involving 40% total body surface area burn. The patient received 260 cm2 of denovoSkin, covering 20% TBSA, as part of a clinical trial sub-study in Italy. The management of such cases represents an unprecedented challenge. […]

Case report: Youngest patient ever treated with denovoSkin – a neonatal case Read More »

Fierce Biotech interview

The leading industry media Fierce Biotech reported on the news that CUTISS sent human skin cells into space, for advanced R&D testing on the International Space Station. Our Chief Innovation Officer Vincent Ronfard explained in his interview the reasons for conducting such experiments and what we hope to achieve. The initial round of experiments will

Fierce Biotech interview Read More »

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine

As part of the company’s R&D in regenerative medicine, CUTISS will observe the effects of space on skin cells and tissue culture. Research implications towards human safety in space travel and new discoveries in regenerative medicine and tissue engineering on Earth. Four-week mission conducted in collaboration with SpacePharma which specializes in space-based experiments and micro-lab

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.